Investors May Cheer CSL's Decision to Delay Seqirus Spinoff -- Market Talk
Dow Jones
Oct 28
2337 GMT - Investors are expected to view CSL's decision to delay a spinoff of flu-vaccine unit Seqirus positively, says RBC Capital Markets analyst Craig Wong-Pan. With U.S. flu-vaccine rates in decline, he says most investors didn't expect the spinoff to create value. Still, Wong-Pan says he expects CSL shares to underperform the market Tuesday given the company's announcement that it is cutting guidance, though he says the tempered growth outlook is "somewhat understandable given it has been mostly attributable to weakness in the influenza vaccine market." CSL shares are down some 15% to about A$180/share. (mike.cherney@wsj.com)
(END) Dow Jones Newswires
October 27, 2025 19:37 ET (23:37 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.